Is Stoke Therapeutics, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from risky to attractive. Based on the analysis, the company appears to be undervalued. Key ratios include a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, indicating strong growth potential relative to its price.
In comparison to its peers, Stoke Therapeutics has a P/E ratio of 12.66, while CorMedix, Inc. is considered expensive with a P/E of 55.03. Taysha Gene Therapies, Inc. is categorized as risky with a negative P/E ratio, further highlighting Stoke's relative attractiveness. Additionally, despite recent stock performance showing a decline of 18.55% over the past year compared to a 10.26% gain in the S&P 500, the valuation metrics suggest that the stock is positioned for potential recovery and growth.